Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Vertex, CRISPR say Casgevy shows promise in younger children

Summary by endpoints.news
Vertex and CRISPR Therapeutics released first data on Monday showing that their landmark gene therapy Casgevy is effective in kids under 12. Casgevy was approved in 2023 for sickle cell disease and won a label ...
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

endpoints.newsendpoints.news

Vertex, CRISPR say Casgevy shows promise in younger children

Vertex and CRISPR Therapeutics released first data on Monday showing that their landmark gene therapy Casgevy is effective in kids under 12. Casgevy was approved in 2023 for sickle cell disease and won a label ...

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

endpoints.news broke the news in on Monday, November 3, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

CRISPR icon

CRISPR

News
For You
SearchBlindspotLocal